Skip to main content
Equibles

VALN · Valneva SE · Webcasts, Transcripts & Audio

Track VALN — free

Use VALN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VALN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.82 +0.08 (+1.31%)
Rebalance outlook locked
Market Cap
$582.22M
Shares
94.82M
Volume · Oct 5 69.39K Avg daily vol (3M) 77.32K

Valneva SE Webcasts

Earnings calls, investor updates, investor days and conferences for Valneva SE (VALN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼5.9% 21.85M EUR −26.04M EUR '22 Q1 22-03-31 ▲53.4% 33.51M EUR −18.13M EUR '23 Q1 23-03-31 ▲50.3% 49.23M EUR −9.23M EUR '25 Q1 25-03-31 LATEST ▼37.2% 30.90M EUR −32.07M EUR '26 Q1 26-05-13
Conference
Investor event
2026-11-16
Valneva SE (VALN) November 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-13
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Positive tone Lyme vaccine (VLA15/LB6V) regulatory progress and outlook Product sales decline and guidance reaffirmation Gross margin pressure and one-off effects
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Valneva SE (VALN) Q1 2026 Earnings Call
Revenue
30.90M EUR
▼ 37.2% YoY
Diluted EPS
-0.18
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-18
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
Positive tone Lyme disease vaccine (VLA15) Chikungunya vaccine (XCHIC/IXCHIC) Shigella vaccine (S4V2)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
Positive tone IXCHIQ (chikungunya vaccine) U.S. suspension Lyme vaccine (VLA15) Phase III Shigella vaccine (S4V2)
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Valneva SE (VALN) Q2 2025 Earnings Call Transcript
Confident tone IXCHIQ (chikungunya vaccine) Lyme disease vaccine (VALOR / VLA15) Commercial product sales (IXIARO, DUKORAL, IXCHIQ)
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Valneva SE (VALN) Q1 2025 Earnings Call Transcript
Positive tone IXCHIQ label extensions, approvals and safety Quarterly financial performance and revenue growth Lyme disease Phase 3 VALOR program
Revenue
49.23M EUR
▲ 50.3% YoY
Diluted EPS
-0.06
▼ 114.6% YoY
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Valneva SE (VALN) Q4 2024 Earnings Call Transcript
Positive tone IXCHIQ commercial ramp and competitive dynamics Lyme vaccine (VLA15) / Phase 3 VALOR Shigella program (S4V2)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Valneva SE (VALN) Q3 2024 Earnings Call Transcript
Positive tone IXCHIQ chikungunya vaccine launch IXIARO Japanese encephalitis vaccine and DOD Lyme disease vaccine (VLA15) program
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Valneva SE (VALN) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Valneva SE (VALN) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Valneva SE (VALN) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Valneva SE (VALN) Q1 2023 Earnings Call Transcript
Revenue
33.51M EUR
▲ 53.4% YoY
Diluted EPS
-0.13
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Valneva SE (VALN) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Valneva SE (VALN) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Valneva SE (VALN) Q1 2022 Earnings Call Transcript
Revenue
21.85M EUR
▼ 5.9% YoY
Diluted EPS
-0.24
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Valneva SE (VALN) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–17 of 17 webcasts
Key facts CIK 1836564 CUSIP 92025Y103 Visit website Investor relations